NBW Capital LLC Acquires 2,650 Shares of Repligen Co. (NASDAQ:RGEN)

NBW Capital LLC raised its holdings in Repligen Co. (NASDAQ:RGEN) by 8.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 33,038 shares of the biotechnology company’s stock after purchasing an additional 2,650 shares during the period. NBW Capital LLC’s holdings in Repligen were worth $5,940,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Fortis Capital Advisors LLC increased its holdings in Repligen by 32.7% in the 1st quarter. Fortis Capital Advisors LLC now owns 272 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 67 shares during the period. Signaturefd LLC increased its holdings in Repligen by 44.1% in the 3rd quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 86 shares during the period. First Horizon Advisors Inc. increased its holdings in Repligen by 14.8% in the 3rd quarter. First Horizon Advisors Inc. now owns 675 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 87 shares during the period. Daiwa Securities Group Inc. grew its holdings in shares of Repligen by 3.2% in the 3rd quarter. Daiwa Securities Group Inc. now owns 3,200 shares of the biotechnology company’s stock worth $509,000 after purchasing an additional 100 shares during the last quarter. Finally, State of Michigan Retirement System grew its holdings in shares of Repligen by 0.8% in the 4th quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock worth $2,239,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Trading Down 2.7 %

Repligen stock traded down $4.38 during trading hours on Thursday, reaching $156.60. 462,124 shares of the company’s stock traded hands, compared to its average volume of 534,642. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 7.02. Repligen Co. has a fifty-two week low of $110.45 and a fifty-two week high of $211.13. The firm has a market capitalization of $8.74 billion, a price-to-earnings ratio of 219.36, a PEG ratio of 5.38 and a beta of 1.02. The firm’s 50 day moving average is $190.02 and its 200-day moving average is $173.20.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. The business had revenue of $155.74 million for the quarter, compared to the consensus estimate of $155.38 million. Repligen had a net margin of 6.51% and a return on equity of 5.00%. Repligen’s revenue for the quarter was down 16.6% on a year-over-year basis. During the same period last year, the company posted $0.68 EPS. On average, analysts predict that Repligen Co. will post 1.46 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Stifel Nicolaus upped their target price on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. KeyCorp upped their target price on shares of Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Finally, JPMorgan Chase & Co. upped their target price on shares of Repligen from $170.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, December 20th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $196.70.

Insider Activity at Repligen

In related news, CEO Anthony Hunt sold 16,707 shares of the stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the sale, the chief executive officer now directly owns 185,249 shares in the company, valued at approximately $36,575,562.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Repligen news, COO James Bylund sold 4,373 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the sale, the chief operating officer now directly owns 14,135 shares in the company, valued at approximately $2,799,860.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Anthony Hunt sold 16,707 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the sale, the chief executive officer now owns 185,249 shares in the company, valued at $36,575,562.56. The disclosure for this sale can be found here. Insiders have sold 25,597 shares of company stock worth $5,039,532 in the last ninety days. Company insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.